Expertise that informs every decision
Our executive leadership brings internationally recognized expertise in disease biology, translational science and human tissue research. Founded by Newcastle University scientists Professors Jelena Mann, Derek Mann, Fiona Oakley and Dr. Lee Borthwick, FibroFind is built on a strong scientific foundation.
Today, our wider leadership team applies that foundation with academic, clinical and commercial insight, helping global biopharma sponsors translate complex science into decision-grade pipeline strategy.
Executive board members
Non-executive board members
Quality-first and always
Rigorous quality control is the foundation of our science.
Guided by ISO 9001 standards and a continuous improvement framework, our operational workflows rely on strict, risk-based project planning to mitigate variability.
Supported by a purpose-built laboratory and advanced automation technology, we safeguard our complex biological processes to ensure that the data we deliver is robust, highly reproducible and replaceable.
Want to connect?
From new studies to established programs that need definitive human validation, we are here to support what comes next.
The ultimate preclinical assurance
Our proprietary bioreactor technology keeps precision-cut tissue slices intact and viable for an extended period as we directly test human biological responses to treatment, translating high-fidelity data into a scalable evidentiary system.
Tissue bioreactor technology
Proprietary bioreactor systems designed to preserve native tissue structure and function, enabling controlled, extended study in living human tissue.
Tissue types and indications
Ethical procurement of viable human liver, lung and kidney tissue through established clinical partnerships for use in our PCTS platforms.
Protecting our global community
For us, ESG is not a corporate box-ticking exercise; it’s a fundamental extension of our core mission to ensure the best science becomes the best medicine. Because our definitive models rely on the gift of human tissue, operating with uncompromising ethical standards is non-negotiable.
To ensure these principles are actively championed rather than just documented, our ESG strategy is overseen directly by our C-suite and driven daily by a dedicated internal team.
Guiding you across the translational gap
We are the preclinical CRO providing expert-led study design that helps close the translational gap, enabling you to test disease directly rather than approximate it.
Our growing team brings together scientists, technical specialists and operational experts with deep experience in chronic disease and human tissue research.
Working in close partnership with drug developers worldwide, we generate the evidence needed for confident, high-stakes decisions, replacing inherited assumptions with the most human-relevant evidence, and giving high-potential assets the strongest possible path to patients.
The evidence your program demands
Speak to our team about your programme.